NCT05188664View on ClinicalTrials.gov

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-302

LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。

DRUG

Toripalimab

Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.

Trial Locations (1)

Unknown

The Alfred, Melbourne

All Listed Sponsors
lead

LaNova Australia Pty Limited

INDUSTRY